COVID-19: How Well Have The Vaccine Makers Performed?

There are currently four major vaccines rolling out around the world. Some of these vaccines have been developed by companies that are listed on exchanges. The amount of business these companies are doing right now is pretty phenomenal. Billions of vaccines are being made in a very short period, helping to boost the books of these companies.

Source: Copyright © 2021 Kalkine Media Pty Ltd

Let us take a look at how some of these companies have moved across the market.

AstraZeneca-Oxford Vaccine

AstraZeneca plc (LON:AZN) is a British-Swedish biopharmaceutical company based out of Cambridge, England. The University of Oxford is also based out of Cambridge, and so a collaborative partnership that produced the two-shot AstraZeneca-Oxford vaccine materialised.

Source: Copyright © 2021 Kalkine Media Pty Ltd

The stock price of AstraZeneca shot up in 2020, before incrementally shifting down a few gears. The Company’s stock rose to a high of GBX 9,320 (closing price) in July 2020 before pulling back down to where it sits today. In the past 52 weeks, the Company’s stock has risen by 12.3%.

On 15 March, by the end of the trading session, AstraZeneca shares quoted GBX 6,988.29, increasing by 0.54%.

Pfizer-BioNTech Vaccine

Pfizer Inc (NYSE:PFE) collaborated with BioNTech SE - ADR (NASDAQ:BNTX) to produce the Pfizer-BioNTech Vaccine. Pfizer is a US-based pharmaceutical company, while BioNTech is a German clinical-stage medicine assessor.

Pfizer’s stock has performed well over the past year, up by 23.9%. Also, BioNTech’s stock performance is a standout among the vaccine producers, rising by 169.7% over the year.

On 15 March, Pfizer shares last traded at US$35.41, increasing by 1.37%. On the same day, BioNTech shares ended at US$107.88, increasing by 4.45%.

Moderna Vaccine

Moderna Inc (NASDAQ:MRNA) is a US pharmaceutical company that develop drugs and vaccines. The Moderna vaccine did not come from a partnership like the vaccines mentioned above.

However, Moderna has recently announced a strategic alliance with the Swiss drug manufacturer, Lonza Group AG (SWX:LONN). Lonza will start creating the ingredients used in the Moderna vaccine to speed up vaccine production.

 Source: Copyright © 2021 Kalkine Media Pty Ltd

Moderna’s stock price has risen the most out of the vaccine producing companies over the past year. Since 16 March 2020, Moderna is up by 442%.

On 15 March, at the time of writing, Moderna shares last traded at US$143.66, increasing 4.87%. While Lonza ended the market session at CHF544.00, decreasing by 0.37%.

Johnson & Johnson Vaccine

Johnson & Johnson (NYSE:JNJ) is a US manufacturer that produces a wide variety of consumer and health products. The Company also has a medical device and biopharmaceutical segment.

Johnson & Johnson’s vaccine is the only one of the four detailed here that is a single shot. However, the efficacy of the vaccine is far less than the others.

Source: © Terovesalainen | Megapixl.com

Johnson & Johnson stock price has risen by 26.2% in the past 52 weeks. Much of the rise came in March and April of 2020, after the announced pre-trial success of its vaccine.

On 15 March, Johnson & Johnson shares last traded at US$160.42, increasing 0.51%.

READ MORE: EU faces AstraZeneca’s COVID-19 vaccine shortage amid manufacturing concerns